Loading...
•
Dec 31, 2021
Ocugen Q4 2021 Earnings Report
Ocugen experienced a transformational year with significant progress across its portfolio, including the lifting of the clinical hold for COVAXIN™ and advancements in gene therapy clinical development.
Key Takeaways
Ocugen reported fourth quarter and full year 2021 financial results, highlighting the lifting of the clinical hold for COVAXIN™, progress in pediatric EUA submission, initiation of a Phase 1/2 clinical trial for OCU400, and a public offering of common stock.
FDA lifted clinical hold on IND application for COVAXIN™, clearing the way for Phase 2/3 clinical trial.
Engagement with FDA to advance pediatric EUA for COVAXIN™ included submission of safety data and neutralization data against Omicron.
Comprehensive responses regarding COVAXIN™ submitted to Health Canada for the NOD.
OCU400 Phase 1/2 clinical trial initiated for the treatment of inherited retinal diseases.
Forward Guidance
Ocugen is poised for another great year in 2022, with plans to commence clinical trials and provide periodic updates.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...